Breakdown | |||
TTM | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|
Income Statement | Total Revenue | ||
55.08M | 44.76M | 17.20M | 243.00K | Gross Profit |
51.30M | -49.65M | 15.47M | -144.00K | EBIT |
-88.47M | -78.49M | -44.64M | -23.95M | EBITDA |
-79.70M | -56.02M | -39.19M | -20.75M | Net Income Common Stockholders |
-73.95M | -68.25M | -43.59M | -21.44M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||
362.13M | 271.18M | 362.13M | 108.15M | Total Assets |
414.49M | 364.84M | 414.49M | 141.99M | Total Debt |
18.57M | 48.23M | 18.57M | 48.93M | Net Debt |
-165.87M | -92.37M | -165.87M | 9.63M | Total Liabilities |
488.91M | 500.43M | 488.91M | 174.54M | Stockholders Equity |
-74.43M | -135.58M | -74.43M | -32.54M |
Cash Flow | Free Cash Flow | ||
-107.91M | -101.22M | 15.75M | 21.35M | Operating Cash Flow |
-103.39M | -91.41M | 29.72M | 24.26M | Investing Cash Flow |
-56.07M | 45.73M | -122.20M | -74.32M | Financing Cash Flow |
82.68M | 1.01M | 239.59M | 39.92M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $4.56B | -16.15 | -11.85% | 4.78% | 31.69% | -53.77% | |
48 Neutral | $3.72B | ― | -19.20% | ― | -89.95% | -123.71% | |
47 Neutral | $2.21B | ― | -43.94% | ― | -83.18% | -144.95% | |
47 Neutral | $75.60M | ― | -30.34% | ― | ― | ― | |
42 Neutral | $206.96M | ― | -156.42% | ― | -74.04% | 48.16% | |
42 Neutral | $129.44M | ― | -98.10% | ― | -58.64% | -40.05% | |
39 Underperform | $962.71M | ― | -54.00% | ― | 59.55% | 3.09% |
On January 13, 2025, Metagenomi, Inc. announced the expansion of its board of directors by appointing Eric Bjerkholt as a new director, effective January 27, 2025. This move is part of Metagenomi’s strategic efforts to strengthen its leadership team as it continues to advance its genetic medicine programs. Bjerkholt’s extensive experience in the biopharmaceutical sector is expected to significantly contribute to the company’s growth and operational strategies. Alongside, Metagenomi updated its presentation for the 43rd Annual J.P. Morgan Healthcare Conference, showcasing its developments in gene editing technologies, which may enhance its competitive standing in the biotechnology market.